Moises Alberto Suarez-Zdunek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Moises Alberto Suarez-Zdunek has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Susanne Dam Nielsen
Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet
10 shared publications - Klaus Fuglsang Kofoed
Department of Cardiology, the Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen
4 shared publications - Andreas Dehlbæk Knudsen
Viro‐immunology Research Unit, Department of Infectious Diseases 8632, Rigshospitalet University of Copenhagen Copenhagen Denmark
3 shared publications - Michael Perch
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
3 shared publications - Shoaib Afzal
Department of Clinical Biochemistry (T.D., S.A., B.G.N.), Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark
3 shared publications - Thomas Benfield
Department of Infectious Diseases Copenhagen University Hospital‐Amager and Hvidovre Hvidovre Denmark
3 shared publications
Latest Publications
- Open Access
Cytomegalovirus Infection and Lung Function in Liver Transplant Recipients: A Nationwide Cohort Study
Impaired lung function is more common among liver transplant recipients than the general population, but the pathogenesis is unknown. We investigated whether prior CMV infections are associated with impaired lung function in liver transplant recipients. We invited adult liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients study (DACOLT) for spirometry and collected data from systematic CMV screening for serostatus and DNAemia. Using linear and logistic regressions adjusted for age, sex, cumulative smoking, and use of inhalation medication, we assessed if prior CMV infections were associated with airflow limitation (FEV 1 /FVC < 0.7 and FEV 1 < 80% of expected) and FEV 1 . Of all eligible liver transplant recipients in Denmark, DACOLT included 600 (79%), and 356 fulfilled the substudy‐specific inclusion criteria. In adjusted models, pretransplant CMV seropositivity was not associated with either airflow limitation (aOR 2.18 [95% CI: 0.71–6.62]) or lower FEV 1 (adjusted β [a β ] = −60 [95% CI: −210 to 80] mL). The same applied to associations between prior CMV DNAemia and airflow limitation (aOR 0.91 [95% CI: 0.35–2.35]) as well as FEV 1 (a β = 30 [95% CI: −120 to 180] mL). This suggests limited clinical impact of CMV infection on posttransplant lung function in liver transplant recipients.
Open AccessCytomegalovirus Infection and Lung Function in Liver Transplant Recipients: A Nationwide Cohort Study
Impaired lung function is more common among liver transplant recipients than the general population, but the pathogenesis is unknown. We investigated whether prior CMV infections are associated with impaired lung function in liver transplant recipients. We invited adult liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients study (DACOLT) for spirometry and collected data from systematic CMV screening for serostatus and DNAemia. Using linear and logistic regressions adjusted for age, sex, cumulative smoking, and use of inhalation medication, we assessed if prior CMV infections were associated with airflow limitation (FEV 1 /FVC < 0.7 and FEV 1 < 80% of expected) and FEV 1 . Of all eligible liver transplant recipients in Denmark, DACOLT included 600 (79%), and 356 fulfilled the substudy‐specific inclusion criteria. In adjusted models, pretransplant CMV seropositivity was not associated with either airflow limitation (aOR 2.18 [95% CI: 0.71–6.62]) or lower FEV 1 (adjusted β [a β ] = −60 [95% CI: −210 to 80] mL). The same applied to associations between prior CMV DNAemia and airflow limitation (aOR 0.91 [95% CI: 0.35–2.35]) as well as FEV 1 (a β = 30 [95% CI: −120 to 180] mL). This suggests limited clinical impact of CMV infection on posttransplant lung function in liver transplant recipients.
- Open Access
- 23 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (10) , e70723
Thymic Involution and Function in People With HIV and General Population Controls: A Cross‐Sectional Analysis From Two Danish Cohort Studies
Thymic involution, the age‐related replacement of thymic soft tissue by fat, has been linked to immunosenescence and chronic inflammation, processes implicated in aging‐associated comorbidities. Untreated HIV infection is associated with thymic atrophy and reduced thymic output. Although thymic function may normalize after initiation of antiretroviral therapy, the long‐term consequences of HIV infection on thymic involution in people with HIV (PWH) remain unknown. We investigated whether thymic involution differs between PWH and population controls, and how its association with markers of T‐cell differentiation and inflammation in PWH. We conducted a cross‐sectional analysis including 654 PWH aged ≥ 40 years from the Copenhagen Comorbidity in HIV Infection study and 637 age‐ and sex‐matched population controls from the Copenhagen General Population Study. Thymic tissue was graded on a 4‐point scale based on adipose‐to‐soft tissue proportion on chest CT scans, with higher grades reflecting more soft tissue (i.e., less involution). Thymic output was assessed by signal joint T‐cell receptor excision circle (sjTREC) content in buffy coats. PWH had higher odds of a higher thymus grade compared to population controls (adjusted‐OR = 1.75, 95% CI = 1.31–2.33), after adjustment for age, sex, pack‐years, BMI, waist‐to‐hip ratio, physical activity, and alcohol intake. Higher thymus grade was associated with greater sjTREC content, and among PWH with higher proportions of naïve CD4 + and CD8 + T cells, lower proportions of senescent T cells, and lower IL‐6 and hs‐CRP levels. Our findings indicate thymic involution may be attenuated in some PWH on long‐term treatment, and that the preserved thymic output may help mitigate chronic inflammation.
- 23 September 2026
- Published by Wiley in Aging Cell
- Vol. 25 (10) , e70723
Open AccessThymic Involution and Function in People With HIV and General Population Controls: A Cross‐Sectional Analysis From Two Danish Cohort Studies
Thymic involution, the age‐related replacement of thymic soft tissue by fat, has been linked to immunosenescence and chronic inflammation, processes implicated in aging‐associated comorbidities. Untreated HIV infection is associated with thymic atrophy and reduced thymic output. Although thymic function may normalize after initiation of antiretroviral therapy, the long‐term consequences of HIV infection on thymic involution in people with HIV (PWH) remain unknown. We investigated whether thymic involution differs between PWH and population controls, and how its association with markers of T‐cell differentiation and inflammation in PWH. We conducted a cross‐sectional analysis including 654 PWH aged ≥ 40 years from the Copenhagen Comorbidity in HIV Infection study and 637 age‐ and sex‐matched population controls from the Copenhagen General Population Study. Thymic tissue was graded on a 4‐point scale based on adipose‐to‐soft tissue proportion on chest CT scans, with higher grades reflecting more soft tissue (i.e., less involution). Thymic output was assessed by signal joint T‐cell receptor excision circle (sjTREC) content in buffy coats. PWH had higher odds of a higher thymus grade compared to population controls (adjusted‐OR = 1.75, 95% CI = 1.31–2.33), after adjustment for age, sex, pack‐years, BMI, waist‐to‐hip ratio, physical activity, and alcohol intake. Higher thymus grade was associated with greater sjTREC content, and among PWH with higher proportions of naïve CD4 + and CD8 + T cells, lower proportions of senescent T cells, and lower IL‐6 and hs‐CRP levels. Our findings indicate thymic involution may be attenuated in some PWH on long‐term treatment, and that the preserved thymic output may help mitigate chronic inflammation.
- Open Access
- 15 July 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (2) , 106814
Systemic inflammatory networks in HIV-associated chronic obstructive pulmonary disease
- 15 July 2026
- Published by Elsevier in Journal of Infection
- Vol. 93 (2) , 106814
Open AccessSystemic inflammatory networks in HIV-associated chronic obstructive pulmonary disease
- Open Access
- 6 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Interferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study
The risk of tuberculosis is increased after solid organ transplantation (SOT) and associated with morbidity and mortality. Pre-transplantation screening and treatment for tuberculosis infection (TBI) is recommended. Aims of this prospective cohort study were determining the prevalence of positive pre-transplantation interferon-gamma release assays (IGRAs), risk factors for a positive result, and describe TBI management. We included SOT candidates from 2020 to 2023 at Rigshospitalet, Denmark with a pre-transplantation IGRA. Data were collected from records and the Danish Microbiology Database. Of 586 patients, 564 (96%) had a pre-transplantation IGRA. Twenty-two (4%) had positive, 537 (95%) negative, and 5 (1%) indeterminate results. Risk factors for a positive IGRA were diabetes (14/480 (3%) without diabetes, 8/84 (10%) with diabetes, aOR 3.07, 95% CI 1.14-7.78), birth in other low-incidence countries (4/24 (17%) vs. 8/463 (2%), aOR 10.14, CI 2.48-35.95) or medium-/high-incidence countries (10/77 (13%), aOR 8.22, CI 3.11-22.43), and alcohol use (aOR 2.75, CI 1.04-7.15). Seventeen patients had TBI; 16 (94%) treated with isoniazid for 6 months, one (6%) with rifampicin for 4 months; treatment discontinued in one case. In conclusion, IGRA screening coverage was high. Positive IGRAs were associated with birth in other low- or medium-/high-incidence countries, diabetes, alcohol use. TBI treatment was well tolerated.
- 6 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessInterferon-gamma release assay screening before solid organ transplantation in a low-incidence country: a prospective single-center cohort study
The risk of tuberculosis is increased after solid organ transplantation (SOT) and associated with morbidity and mortality. Pre-transplantation screening and treatment for tuberculosis infection (TBI) is recommended. Aims of this prospective cohort study were determining the prevalence of positive pre-transplantation interferon-gamma release assays (IGRAs), risk factors for a positive result, and describe TBI management. We included SOT candidates from 2020 to 2023 at Rigshospitalet, Denmark with a pre-transplantation IGRA. Data were collected from records and the Danish Microbiology Database. Of 586 patients, 564 (96%) had a pre-transplantation IGRA. Twenty-two (4%) had positive, 537 (95%) negative, and 5 (1%) indeterminate results. Risk factors for a positive IGRA were diabetes (14/480 (3%) without diabetes, 8/84 (10%) with diabetes, aOR 3.07, 95% CI 1.14-7.78), birth in other low-incidence countries (4/24 (17%) vs. 8/463 (2%), aOR 10.14, CI 2.48-35.95) or medium-/high-incidence countries (10/77 (13%), aOR 8.22, CI 3.11-22.43), and alcohol use (aOR 2.75, CI 1.04-7.15). Seventeen patients had TBI; 16 (94%) treated with isoniazid for 6 months, one (6%) with rifampicin for 4 months; treatment discontinued in one case. In conclusion, IGRA screening coverage was high. Positive IGRAs were associated with birth in other low- or medium-/high-incidence countries, diabetes, alcohol use. TBI treatment was well tolerated.
- Open Access
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag311
Inter-arm Blood Pressure Difference is Associated With Both Coronary Artery Disease and Peripheral Artery Disease in People With HIV
High systolic inter-arm blood pressure difference (SIABPD) is associated with cardiovascular events. We evaluated the prevalence of high SIABPD and its association with coronary and peripheral artery disease in people with HIV. The prevalence of high SIABPD was 24%, and SIABPD was independently associated with extensive coronary and peripheral arterial disease.
- 2 June 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (6) , ofag311
Open AccessInter-arm Blood Pressure Difference is Associated With Both Coronary Artery Disease and Peripheral Artery Disease in People With HIV
High systolic inter-arm blood pressure difference (SIABPD) is associated with cardiovascular events. We evaluated the prevalence of high SIABPD and its association with coronary and peripheral artery disease in people with HIV. The prevalence of high SIABPD was 24%, and SIABPD was independently associated with extensive coronary and peripheral arterial disease.
- Open Access
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70468
Soluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients
Background and Aims: Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan. Methods: In the Danish Comorbidity in Liver Transplant Recipients study (DACOLT) we included 105 LT recipients at Aarhus University Hospital. We reviewed patient records and collected plasma for measurements of sCD163 and FIB‐4. Liver stiffness was assessed using FibroScan. Liver biopsies performed n = 33) were investigated by the Banff score and the METAVIR fibrosis score. Results: The majority (86%) had FibroScan with transient elastography ρ = 0.38, p < 0.001) and remained independently associated after multivariable adjustment (β = 0.14, p < 0.0002), corresponding to a 15.2% increase in liver stiffness per 1 mg/L increase in sCD163. In patients with liver biopsies, sCD163 levels were significantly higher in those with METAVIR stage F2–F4 compared to F0–F1 (5.04 vs. 2.35 mg/L, p = 0.018), and sCD163 correlated with histological fibrosis stage ( ρ = 0.40, p = 0.029). At a cutoff of 3.86 mg/L, sCD163 identified METAVIR F2–4 fibrosis with 80% sensitivity and 85% specificity (AUC = 0.94). Conclusions: In this cohort of LT recipients, sCD163 was associated with both liver stiffness and histological fibrosis. These findings support sCD163 as a promising noninvasive biomarker for detection and monitoring of liver fibrosis post‐LT, warranting evaluation in larger, prospective studies.
- 30 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (2) , e70468
Open AccessSoluble CD163 as a Biomarker of Liver Fibrosis and Inflammation in Liver Transplant Recipients
Background and Aims: Post liver transplantation (LT) inflammation and fibrosis are clinical challenges that may affect long‐term outcomes. We aimed to investigate sCD163 as a biomarker of liver fibrosis in LT recipients and compare it with the Fibrosis 4 (FIB‐4) score and FibroScan. Methods: In the Danish Comorbidity in Liver Transplant Recipients study (DACOLT) we included 105 LT recipients at Aarhus University Hospital. We reviewed patient records and collected plasma for measurements of sCD163 and FIB‐4. Liver stiffness was assessed using FibroScan. Liver biopsies performed n = 33) were investigated by the Banff score and the METAVIR fibrosis score. Results: The majority (86%) had FibroScan with transient elastography ρ = 0.38, p < 0.001) and remained independently associated after multivariable adjustment (β = 0.14, p < 0.0002), corresponding to a 15.2% increase in liver stiffness per 1 mg/L increase in sCD163. In patients with liver biopsies, sCD163 levels were significantly higher in those with METAVIR stage F2–F4 compared to F0–F1 (5.04 vs. 2.35 mg/L, p = 0.018), and sCD163 correlated with histological fibrosis stage ( ρ = 0.40, p = 0.029). At a cutoff of 3.86 mg/L, sCD163 identified METAVIR F2–4 fibrosis with 80% sensitivity and 85% specificity (AUC = 0.94). Conclusions: In this cohort of LT recipients, sCD163 was associated with both liver stiffness and histological fibrosis. These findings support sCD163 as a promising noninvasive biomarker for detection and monitoring of liver fibrosis post‐LT, warranting evaluation in larger, prospective studies.
- Open Access
- 19 January 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (1) , 225
Prevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis
Prior to the introduction of antiretroviral therapy (ART), people with HIV (PWH) had high risk of fungemia. No systematic review has assessed the prevalence of fungemia in PWH after the introduction of combination ART in 1996. The primary objective of this systematic review was to determine the prevalence of fungemia in adult PWH after 1996. Furthermore, we aimed to compare the prevalence of fungemia in different ART time periods to determine geographic differences and fungal pathogen distribution. A systematic literature search was performed on 7 March 2025 across six databases and the study quality was assessed using the Newcastle–Ottawa scale. Prevalence estimates were extracted, and a meta-analysis was performed using a random effects model. Twelve studies comprising 27,729 PWH were included. The overall pooled prevalence in PWH was 3.3% (95% CI: 1.53; 4.96%, I2 = 98.9%). The most common pathogen to cause fungemia was Talaromyces marneffei with a prevalence of 4.8%, although this pathogen was limited to studies from Asia. The highest prevalence of fungemia in PWH was 6.8% in Asia. The prevalence of fungemia was 5.8% between July 1996–September 2015 and 1.0% between September 2015–January 2025, but the difference was not statistically significant (p = 0.273). However, all findings were limited by very low certainty of evidence and should be interpreted with caution. In conclusion, our findings suggest that fungemia persists among PWH despite ART, especially in Asia. Given the limited available evidence, it was not possible to determine whether the prevalence of fungemia changed following the change in ART treatment guidelines in September 2015. The protocol is registered in PROSPERO (CRD420251005081).
- 19 January 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (1) , 225
Open AccessPrevalence of Fungemia in People with HIV: A Systematic Review and Meta-Analysis
Prior to the introduction of antiretroviral therapy (ART), people with HIV (PWH) had high risk of fungemia. No systematic review has assessed the prevalence of fungemia in PWH after the introduction of combination ART in 1996. The primary objective of this systematic review was to determine the prevalence of fungemia in adult PWH after 1996. Furthermore, we aimed to compare the prevalence of fungemia in different ART time periods to determine geographic differences and fungal pathogen distribution. A systematic literature search was performed on 7 March 2025 across six databases and the study quality was assessed using the Newcastle–Ottawa scale. Prevalence estimates were extracted, and a meta-analysis was performed using a random effects model. Twelve studies comprising 27,729 PWH were included. The overall pooled prevalence in PWH was 3.3% (95% CI: 1.53; 4.96%, I2 = 98.9%). The most common pathogen to cause fungemia was Talaromyces marneffei with a prevalence of 4.8%, although this pathogen was limited to studies from Asia. The highest prevalence of fungemia in PWH was 6.8% in Asia. The prevalence of fungemia was 5.8% between July 1996–September 2015 and 1.0% between September 2015–January 2025, but the difference was not statistically significant (p = 0.273). However, all findings were limited by very low certainty of evidence and should be interpreted with caution. In conclusion, our findings suggest that fungemia persists among PWH despite ART, especially in Asia. Given the limited available evidence, it was not possible to determine whether the prevalence of fungemia changed following the change in ART treatment guidelines in September 2015. The protocol is registered in PROSPERO (CRD420251005081).
- Open Access
Booster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV. We aimed to determine the seroprotection rates and changes in antibody concentrations after booster vaccination against IPD and HBV in SOT recipients without post-transplantation seroprotection after pre-transplantation vaccination. Furthermore, we aimed to identify risk factors associated with non-response to booster vaccination. Methods: In this prospective cohort study, we included adult SOT recipients without post-transplantation seroprotection against IPD who then received the 23-valent pneumococcal polysaccharide vaccine (PPSV23) booster, as well as adult SOT recipients without seroprotection against HBV who then received the Engerix-B® booster after pre-transplantation vaccination. Logistic regression models were used to analyze risk factors for non-response to booster vaccination. Results: We included 50 SOT recipients in analyses of booster vaccination against IPD and 52 SOT recipients in analyses of booster vaccination against HBV. Seroprotection rates were 52% after booster vaccination against IPD and 7.7% after booster vaccination against HBV. The median geometric mean concentration of pneumococcal antibodies increased from 0.54 µg/mL IgG (interquartile range, IQR: 0.35–0.77) to 1.21 µg/mL IgG (IQR: 0.87–1.62) after booster vaccination (p < 0.001). Having pre-transplantation seroprotection against IPD at time of listing was associated with lower odds of non-response to booster vaccination. We were not able to identify risk factors for non-response to HBV booster vaccination. Conclusions: Booster vaccination improved seroprotection against IPD, but not HBV. Further studies are needed to examine optimal vaccination strategies for SOT recipients.
Open AccessBooster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV. We aimed to determine the seroprotection rates and changes in antibody concentrations after booster vaccination against IPD and HBV in SOT recipients without post-transplantation seroprotection after pre-transplantation vaccination. Furthermore, we aimed to identify risk factors associated with non-response to booster vaccination. Methods: In this prospective cohort study, we included adult SOT recipients without post-transplantation seroprotection against IPD who then received the 23-valent pneumococcal polysaccharide vaccine (PPSV23) booster, as well as adult SOT recipients without seroprotection against HBV who then received the Engerix-B® booster after pre-transplantation vaccination. Logistic regression models were used to analyze risk factors for non-response to booster vaccination. Results: We included 50 SOT recipients in analyses of booster vaccination against IPD and 52 SOT recipients in analyses of booster vaccination against HBV. Seroprotection rates were 52% after booster vaccination against IPD and 7.7% after booster vaccination against HBV. The median geometric mean concentration of pneumococcal antibodies increased from 0.54 µg/mL IgG (interquartile range, IQR: 0.35–0.77) to 1.21 µg/mL IgG (IQR: 0.87–1.62) after booster vaccination (p < 0.001). Having pre-transplantation seroprotection against IPD at time of listing was associated with lower odds of non-response to booster vaccination. We were not able to identify risk factors for non-response to HBV booster vaccination. Conclusions: Booster vaccination improved seroprotection against IPD, but not HBV. Further studies are needed to examine optimal vaccination strategies for SOT recipients.
- Open Access
- 11 March 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 401
Association Between hsTnT and NT-proBNP and Peripheral Artery Disease in People with HIV: A Multicentre Danish Cohort Study
People with HIV (PWH) have a high risk of peripheral artery disease (PAD), and high-sensitivity troponin (hsTnT) and NT-pro B-type natriuretic peptide (NT-proBNP) may be useful biomarkers for PAD in PWH. We assessed associations between hsTnT and NT-proBNP and both prevalent PAD and de novo PAD. Adult PWH were examined at baseline and after 2 years. Inclusion criteria were (1) measurements of hsTnT and NT-proBNP at baseline and (2) ankle brachial index (ABI) at baseline for prevalent PAD and both visits for de novo PAD. PAD was defined as ABI ≤ 0.9. We included 1011 PWH, and 88 (8.7%) had PAD at baseline. Among 802 PWH, 29 (3.6%) had de novo PAD at follow-up. A doubling in hsTnT concentration was associated with prevalent PAD with an OR 1.41 (95% CI: 1.02–1.96, p = 0.04) and 1.40 (95% CI: 0.99–1.98, p = 0.055) in a base model and an adjusted model, respectively. High hsTnT was associated with a risk ratio of 3.39 (95% CI: 1.24–9.27, p = 0.02) for de novo PAD in an unadjusted model and 3.44 (95% CI: 0.98–12.10, p = 0.05) after adjustments. NT-proBNP was not associated with PAD. Thus, hsTnT was associated with higher odds of prevalent PAD and increased risk of de novo PAD.
- 11 March 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 401
Open AccessAssociation Between hsTnT and NT-proBNP and Peripheral Artery Disease in People with HIV: A Multicentre Danish Cohort Study
People with HIV (PWH) have a high risk of peripheral artery disease (PAD), and high-sensitivity troponin (hsTnT) and NT-pro B-type natriuretic peptide (NT-proBNP) may be useful biomarkers for PAD in PWH. We assessed associations between hsTnT and NT-proBNP and both prevalent PAD and de novo PAD. Adult PWH were examined at baseline and after 2 years. Inclusion criteria were (1) measurements of hsTnT and NT-proBNP at baseline and (2) ankle brachial index (ABI) at baseline for prevalent PAD and both visits for de novo PAD. PAD was defined as ABI ≤ 0.9. We included 1011 PWH, and 88 (8.7%) had PAD at baseline. Among 802 PWH, 29 (3.6%) had de novo PAD at follow-up. A doubling in hsTnT concentration was associated with prevalent PAD with an OR 1.41 (95% CI: 1.02–1.96, p = 0.04) and 1.40 (95% CI: 0.99–1.98, p = 0.055) in a base model and an adjusted model, respectively. High hsTnT was associated with a risk ratio of 3.39 (95% CI: 1.24–9.27, p = 0.02) for de novo PAD in an unadjusted model and 3.44 (95% CI: 0.98–12.10, p = 0.05) after adjustments. NT-proBNP was not associated with PAD. Thus, hsTnT was associated with higher odds of prevalent PAD and increased risk of de novo PAD.